Cho CK - Search Results

1

Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19.

Park HJ, Lee SH, Kang P, Cho CK, Jang CG, Lee SY, Lee YJ, Bae JW, Choi CI. Park HJ, et al. Among authors: cho ck. Arch Pharm Res. 2025 Jan 6. doi: 10.1007/s12272-024-01528-8. Online ahead of print. Arch Pharm Res. 2025. PMID: 39760829

2

Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects.

Jung EH, Lee CM, Byeon JY, Shin HB, Oh KY, Cho CK, Lim CW, Jang CG, Lee SY, Lee YJ. Jung EH, et al. Among authors: cho ck. Arch Pharm Res. 2020 Sep;43(9):976-981. doi: 10.1007/s12272-020-01250-1. Epub 2020 Jul 13. Arch Pharm Res. 2020. PMID: 32661920

3

Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.

Jung EH, Lee YJ, Kim DH, Kang P, Lim CW, Cho CK, Jang CG, Lee SY, Bae JW. Jung EH, et al. Among authors: cho ck. Arch Pharm Res. 2020 Dec;43(12):1356-1363. doi: 10.1007/s12272-020-01300-8. Epub 2020 Nov 27. Arch Pharm Res. 2020. PMID: 33245517

4

Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.

Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ. Bae JW, et al. Among authors: cho ck. Arch Pharm Res. 2020 Nov;43(11):1207-1213. doi: 10.1007/s12272-020-01293-4. Epub 2020 Nov 27. Arch Pharm Res. 2020. PMID: 33247397

5

ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan.

Shin HB, Jung EH, Kang P, Lim CW, Oh KY, Cho CK, Lee YJ, Choi CI, Jang CG, Lee SY, Bae JW. Shin HB, et al. Among authors: cho ck. Arch Pharm Res. 2020 Nov;43(11):1187-1196. doi: 10.1007/s12272-020-01294-3. Epub 2020 Nov 29. Arch Pharm Res. 2020. PMID: 33249530

6

Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.

Kim YH, Kang P, Cho CK, Jung EH, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY. Kim YH, et al. Among authors: cho ck. Arch Pharm Res. 2021 Jul;44(7):713-724. doi: 10.1007/s12272-021-01346-2. Epub 2021 Jul 25. Arch Pharm Res. 2021. PMID: 34304363 Clinical Trial.

7

Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele.

Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY. Cho CK, et al. Arch Pharm Res. 2021 Nov;44(11):1037-1049. doi: 10.1007/s12272-021-01357-z. Epub 2021 Nov 9. Arch Pharm Res. 2021. PMID: 34751931 Clinical Trial.

8

Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.

Cho CK, Park HJ, Kang P, Moon S, Lee YJ, Bae JW, Jang CG, Lee SY. Cho CK, et al. Arch Pharm Res. 2021 Dec;44(12):1076-1090. doi: 10.1007/s12272-021-01361-3. Epub 2021 Nov 22. Arch Pharm Res. 2021. PMID: 34807366

9

Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients.

Jung EH, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Choi CI, Jang CG, Lee SY. Jung EH, et al. Among authors: cho ck. Arch Pharm Res. 2021 Dec;44(12):1109-1119. doi: 10.1007/s12272-021-01363-1. Epub 2021 Nov 24. Arch Pharm Res. 2021. PMID: 34817825

10

Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.

Kim NT, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY. Kim NT, et al. Among authors: cho ck. Arch Pharm Res. 2022 Feb;45(2):114-121. doi: 10.1007/s12272-021-01366-y. Epub 2021 Dec 24. Arch Pharm Res. 2022. PMID: 34952963

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

328 results

Search Page

Filters